There’s a conversation that happens constantly in health tech, usually when product development is consuming everything and the pipeline feels just stable enough to deprioritize everything else.
It goes something like this: We’ll invest in marketing once we’ve got more traction. Once the product is ready. Once we close this next deal. Once we have more bandwidth.
It’s an understandable impulse. Marketing feels optional when you’re heads-down building something real. But here’s what most health tech founders don’t realize until they’re already behind: not investing in marketing isn’t a neutral decision. It’s a costly one. And the damage compounds quietly, long before it shows up in your numbers.
The Pipeline Problem You Don’t See Coming
B2B healthcare sales cycles are long. Depending on the solution and the buyer, you’re often looking at 6 to 18 months from first awareness to signed contract. That timeline has a critical implication that’s easy to miss: the deals you need to close a year from now are being influenced by what you’re doing (or not doing) today.
Marketing doesn’t just generate leads and awareness; it seeds your future pipeline. Every article published, every email sent, every LinkedIn post that surfaces in a decision-maker’s feed is a touchpoint that builds familiarity, credibility, and trust over time. When you go quiet, you’re not just losing visibility in the present. You’re pulling up the roots of future revenue.
The founders who feel the sharpest pain aren’t usually the ones who never marketed. They’re the ones who did, stopped, and then tried to figure out why the pipeline dried up six months later.
What Your Buyers Are Doing While You’re Silent
Here’s something worth sitting with: your buyers don’t wait for you to reach out. They research.
Before a health system VP, a benefits director, or a CMO ever takes a sales call, they’ve already formed an impression of who you are. If you’re not marketing, they haven’t formed one at all. They’ve read your content, noticed your absence, or redirected their attention to whoever was consistently showing up. By the time a buyer is ready to make a decision, a significant portion of their trust has already been allocated.
That trust is built through repeated exposure over time. A single great pitch deck doesn’t earn it. A flurry of activity around a conference doesn’t earn it. Consistent, relevant, credible content published steadily, week after week and month after month is what earns it.
And in healthcare specifically, the bar is higher than in other industries. The stakes of buying decisions are real. Buyers are cautious. They need to see sustained expertise and visible credibility before they’ll stake their reputation on recommending a vendor internally. If you’re not consistently building that credibility, your competitors are.
The Compounding Cost of Going Dark
One of the most damaging myths in early-stage marketing is that you can pause and resume without consequence. That you can go quiet for a quarter, or two, or four, and then turn it back on when the timing is better.
That’s not how it works.
Marketing builds momentum. Content earns SEO equity over time. Email lists grow warmer with consistent nurturing and colder with every week of silence. Social audiences that stop seeing your name stop thinking about you. And when you decide to restart, you’re not picking up where you left off. You’re starting over, often at a deficit, working to rebuild what you let decay.
The restart is almost always harder and more expensive than simply staying consistent in the first place.
There’s also a compounding advantage at work on the other side of this equation. The healthtech companies that maintain steady marketing momentum don’t just stay visible; they accelerate. Each piece of content reinforces the last. Each touchpoint deepens the relationship. Authority compounds. And when a buyer is finally ready to make a move, the consistently visible company has a head start that the quiet one simply can’t close overnight.
What “Investing in Marketing” Actually Means at Early Stage
This is worth clarifying because the word investment can feel heavy when budgets are tight and bandwidth is thin. Investing in marketing doesn’t mean a full agency retainer, a trade show booth, and a paid media budget. At the early stage, it means something more targeted, and much more achievable.
It means a consistent thought leadership cadence. Articles, LinkedIn content, and a newsletter that position your team as credible voices on the problems your buyers actually care about. Not product promotion…problem-focused expertise. The 3-to-1 rule applies here: aim for at least three value-driven touchpoints for every one sales ask. Buyers will tune you out the moment they feel like every communication is a pitch.
It means a healthy, actively maintained contact list that is carefully sourced, verified, and nurtured with content that earns attention rather than demands it.
And it means a marketing partner or team member who can keep the engine running even when you’re heads-down. Because the moments when you’re most tempted to deprioritize marketing to put focus on a big product push, a critical hiring cycle, a major deal in the works, are often the moments your buyers are most actively paying attention.
The Longer You Wait, the More It Costs
The founders who figure this out early have a significant advantage. They’re building brand equity, warming their audiences, and seeding the pipeline while their peers are still waiting for the right moment.
The right moment isn’t coming. There is no version of your business where you have more time, a cleaner product, or an easier competitive landscape waiting just around the corner. The window to build trust with buyers in your market is right now. For every month you’re not in it, someone else is.
Not investing in marketing doesn’t save you money. It defers a cost that will eventually come due, with interest.
